MOTS-c regulatory status
Current status of MOTS-c in the United States: HHS interim policy (draft). In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of MOTS-c?
- FDA and compounding
- MOTS-c is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds MOTS-c when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add MOTS-c to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.
- WADA
- WADA prohibited
- Access path
- Compounded access under HHS's draft policy (announced October 28, 2026): HHS says it does not intend to take enforcement action when a state-licensed pharmacy or licensed physician compounds single-ingredient MOTS-c by injection under the skin or into muscle on a patient-specific prescription, under strict quality and reporting conditions. The policy is a draft, is not binding, and HHS may revisit it. Blends and stacks are not covered, and state law still applies.
- Not available as an FDA approved product.
- Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.
Full MOTS-c page: evidence, dosing in the literature, and sources
Is MOTS-c FDA approved or legal? Questions and answers
Is MOTS-c FDA approved?
No. MOTS-c is not an FDA approved drug for any use. FDA placed it on the 503A Category 2 list in 2023, and FDA's list dated April 22, 2026 shows the nomination as withdrawn. At the July 23, 2026 compounding advisory committee meeting, FDA's drug center (CDER) recommended against listing it and the committee voted in favor (HHS policy, Appendix B). A committee vote is advisory and is not an approval. HHS's October 28, 2026 draft enforcement discretion policy is not an approval either: HHS only says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient MOTS-c for a named patient on a prescription, under strict conditions. [1] [2] [3] [4] [5]
What is the FDA status of MOTS-c in 2026?
HHS interim policy (draft). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds MOTS-c as a single-ingredient product by an allowed route (subcutaneous or intramuscular injection), on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. It is not an FDA approval or a 503A bulks listing, it is not binding, and HHS may revisit it; comments are open through November 13, 2026. Before that, MOTS-c was in 503A Category 2 from September 2023 until April 22, 2026, when its nomination was withdrawn, and at the July 23, 2026 advisory committee meeting FDA's drug center (CDER) recommended against listing it while the committee voted in favor (HHS policy, Appendix B). Blends and stacks are not covered. [2] [3] [4] [5]
Is MOTS-c banned by WADA?
Yes. MOTS-c is named on the WADA Prohibited List under section S4.4 (metabolic modulators) as an activator of AMP-activated protein kinase, and it is prohibited at all times, in and out of competition. [6]
How has the status of MOTS-c changed over time?
- HHS
HHS draft policy lets licensed pharmacies compound six peptides without enforcement action
HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- PCAC
FDA advisory committee reviews six peptides; FDA's briefing recommends against listing
At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.
Regulatory: Nomination withdrawnSource: FDA: Pharmacy Compounding Advisory Committee, July 23, 2026, FDA presentation slides - FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- FDA
FDA places a batch of nominated peptides in 503A Category 2
In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for MOTS-c and the source of each dated event.
- [1]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (503A Category 2 list and nominated but withdrawn substances, current as of April 22, 2026)FDA, 2026
- [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [3]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [4]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history)2026
- [5]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496)Federal Register, 2026
- [6]WADA Prohibited List, section S4.4 metabolic modulatorsWADA, 2026
- [7]WADA 2027 Prohibited List (published September 21, 2026, in force January 1, 2027)WADA, 2026
- [8]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [9]FDA: Pharmacy Compounding Advisory Committee, July 23, 2026, FDA presentation slidesFDA, 2026
From the blog
- MOTS-c side effects and benefits: what the evidence shows
No published human study has reported MOTS-c side effects, because none has given it to people and posted results. The mouse benefit claims, the safety gaps FDA named, and its legal status.
- MOTS-c for weight loss: what mouse and human studies show
MOTS-c prevented diet-induced obesity in mice, but no human trial has tested it for weight loss. What the mouse data show, what human blood studies found, and where it stands legally.
- RFK Jr.'s peptide policy: what HHS changed for BPC-157 and five other peptides
HHS released a draft policy on October 28, 2026: it will not act against licensed compounding of BPC-157, TB-500, epitalon, KPV, MOTS-c, or semax under strict conditions. It is not FDA approval.